CN113274398B - Nano self-assembly material for inhibiting tumor cell glycometabolism and preparation method and application thereof - Google Patents
Nano self-assembly material for inhibiting tumor cell glycometabolism and preparation method and application thereof Download PDFInfo
- Publication number
- CN113274398B CN113274398B CN202110442089.7A CN202110442089A CN113274398B CN 113274398 B CN113274398 B CN 113274398B CN 202110442089 A CN202110442089 A CN 202110442089A CN 113274398 B CN113274398 B CN 113274398B
- Authority
- CN
- China
- Prior art keywords
- nano self
- pei
- dspe
- mpeg
- assembly material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
The invention discloses a nano self-assembly material for inhibiting tumor cell glycometabolism and a preparation method and application thereof. The nano self-assembly material is prepared by stirring a mixture of mPEG-SS-PEI-DSPE long chain, adriamycin and DNA ligand in an aqueous solution at room temperature, then dissolving glucose transporter inhibitor BAY-876 in chloroform, heating while performing ultrasonic treatment in the system, and performing freeze-drying to obtain the nano self-assembly material with the structure of BAY-876@ (mPEG-SS-PEI-DSPE-Dox-Duplex), and can well inhibit the glycometabolism of tumor cells. The invention is synthesized by adopting a one-step method, and the nano material can well release Dox and BAY-876 which respectively act on DNA and glucose transport protein of tumor cells, inhibit energy metabolism of the tumor cells and limit growth and reproduction of the tumor cells.
Description
Technical Field
The invention relates to a nano self-assembly material for inhibiting tumor cell glycometabolism and a preparation method and application thereof, belonging to the field of biological material research.
Background
According to the analysis of global cancer statistical data, as of 2018, the number of newly-added cancer confirmed cases in the world is far more than 1800 thousands, wherein the number of deaths is more than 960 thousands, and the number of deaths in Asia accounts for more than 70% of the total number of deaths in Asia, so that the people feel surprise. At present, the clinical treatment means aiming at the tumor mainly comprises three traditional tumor treatment means, namely surgery, radiotherapy and drug therapy (chemotherapy). Although these treatment methods have been widely applied to clinical tumor treatment, the surgical treatment can not be completely removed, which results in tumor recurrence and metastasis, tumor resistance caused by chemotherapy, and indiscriminate damage of radiotherapy to peripheral normal tissues, and the requirements of modern tumor treatment cannot be met. Compared with traditional tumor treatment modes, emerging nanomedicine shows stronger specificity, richer functionality and smaller side effects. However, in the face of a large variety of solid tumors with complex and varied microenvironments (including weak acidity, oxygen deficiency, high active oxygen concentration, multiple overexpressed enzymes, reductive microenvironments and the like), the treatment effect exhibited by the nano-drug is not satisfactory. For example, the oxygen-dependent treatment efficiency caused by tumor hypoxia is low, the photosensitive treatment efficiency caused by weak light penetration is low, the tumor recurrence caused by the rise of inflammatory factors caused by photo-thermal treatment is caused, and the like, and the tumor treatment is incomplete, easy to recur and easy to transfer due to the above reasons.
Glucose, which is the most widely distributed and important monosaccharide in nature, is a living cell energy source and a metabolic intermediate product, i.e., a main energy supply substance of organisms, and is also the most important source of human body heat energy. After being digested by human body, ordinary food is mainly absorbed and utilized in the form of glucose. Glucose can participate in the respiration of cells in the cells, is quickly oxidized and releases ATP, and supplies various physiological activities to the cells. In addition, glycolipids formed from glucose and lipids are components that make up cell membranes and nervous tissues, and are combined with proteins to form glycoproteins that can constitute antibodies, certain enzymes, hormones, and other substances with important biological activities. Therefore, rational control of glucose in tumor cells can limit the growth and proliferation of tumor cells.
Zhang et al (ACS Nano 2017,11,1419-1431) coat diclofenac as an inhibitor of glucose transporter 1 outside a gold rod, deliver the diclofenac into tumor cells, inhibit the activity of the glucose transporter 1, limit the energy metabolism of the tumor cells, and perform photothermal therapy on tumors by utilizing the photothermal action of the gold rod. Under various treatment modes, the tumor cells can be well killed. Wei et al (J.Mater.chem.B.2018, 6, 2078-2088) deliver Cu2+ and a photosensitizer of Zn2+ as organometallic skeleton compounds into tumor cells, and utilize the affinity between Cu2+ and ATP to reduce the ATP content in the tumor cells, limit the energy metabolism, and reduce the tolerance of the tumor cells, thereby enhancing the photodynamic therapy effect and successfully killing the tumor cells.
Disclosure of Invention
The invention aims to provide a nano self-assembly material for inhibiting tumor cell glycometabolism and a preparation method and application thereof.
The technical scheme adopted by the invention is as follows:
a preparation method of a nano self-assembly material for inhibiting tumor cell glycometabolism comprises the following steps:
s1, mixing adriamycin and DNA ligand at room temperature to obtain a mixture Dox-Duplex, adding the mPEG-SS-PEI-DSPE long chain and the mixture Dox-Duplex into deionized water, uniformly stirring in an aqueous solution system, and performing ultrasonic treatment for 10-30 minutes to obtain an aqueous solution of the mPEG-SS-PEI-DSPE-Dox-Duplex;
s2, dissolving a glucose transporter inhibitor BAY-876 in chloroform, slowly dropping the solution into the aqueous solution system of mPEG-SS-PEI-DSPE-Dox-Duplex obtained in the step (1), heating while performing ultrasonic treatment, keeping the temperature not higher than 50 ℃ until the liquid becomes clear and transparent, centrifuging and freeze-drying to obtain the nano self-assembly material with the structure of BAY-876@ (mPEG-SS-PEI-DSPE-Dox-Duplex).
Further, in step S1, the molar ratio of the doxorubicin to the DNA ligand is 1: 2.
further, the base sequences of the DNA ligands in step S1 are 5'-ACC TGG GGG AGT ATT GCG GAG GAA GGT-3' and 5'-ACC TTC CTC CGC AAT ACT CCC CCA GGT-3'.
Further, the mass ratio of the added mPEG-SS-PEI-DSPE to Dox-Duplex to BAY-876 is 1-5: 1: 1.
Further, in step S1, the mPEG-SS-PEI-DSPE has a structure of polyethylene glycol-disulfide bond-polyethyleneimine-distearoylphosphatidylethanolamine, wherein the molecular weight of the polyethylene glycol is 2000, and the molecular weight of the polyethyleneimine is 1800.
Further, the mole ratio of the mPEG-SS-PEI-DSPE long chain added into the deionized water to the mixture Dox-Duplex in the step S1 is 1: 1.
further, the volume ratio of the trichloromethane in the step S2 to the deionized water in the step S1 is 1: 10-20.
Further, in step S1, the ratio of mPEG-SS-PEI-DSPE to deionized water is 1 mg: 1-5 mL.
In the nano self-assembly material with the structure of BAY-876@ (mPEG-SS-PEI-DSPE-Dox-Duplex) prepared by the method, a mixture of adriamycin and DNA ligand is adsorbed with polyethyleneimine in a long chain of mPEG-SS-PEI-DSPE through electrostatic interaction, and BAY-876 is combined with distearoyl phosphatidyl ethanolamine and stored in the center of the nano self-assembly material.
The nano self-assembly material for inhibiting the carbohydrate metabolism of the tumor cells is applied to tumor treatment, and is used for inhibiting the glucose metabolism and ATP (adenosine triphosphate) production of tumors so as to limit the growth and proliferation of the tumor cells
Has the advantages that: the nano self-assembly material for inhibiting the sugar metabolism of tumor cells, the preparation method and the application thereof have the following advantages:
(1) the preparation method of the nano self-assembly material is simple, the preparation process is simple and efficient, the reaction can be completed in one step, a plurality of complicated synthetic steps are reduced, and the synthetic method is simple and clear.
(2) The nano self-assembly material prepared by the invention can better respond to the micro-environment of tumors, release Dox and BAY-876 and has no harm to normal tissue cells.
(3) The nano self-assembly material prepared by the invention can well inhibit glucose metabolism and ATP generation of tumors and limit growth and proliferation of tumor cells.
Drawings
FIG. 1 is a flow chart of the method for preparing the nano self-assembly material of the present invention.
FIG. 2 is a Transmission Electron Microscope (TEM) image of the nano self-assembled material of the present invention.
FIG. 3 is a distribution diagram of the particle size of the nano self-assembly material of the present invention.
FIG. 4 is a schematic diagram of the inhibition effect of the nano self-assembly material of the present invention on glucose uptake and ATP synthesis of tumor cells.
Detailed Description
The invention is described in further detail below with reference to the figures and examples. Generally, the preparation method of the nano self-assembly material for inhibiting the sugar metabolism of the tumor cells comprises the following steps:
s1, mPEG-SS-PEI-DSPE-Dox-Duplex nano-system construction: mixing adriamycin and DNA ligand at room temperature, wherein the base sequences of the DNA ligand are 5'-ACC TGG GGG AGT ATT GCG GAG GAA GGT-3' and 5'-ACC TTC CTC CGC AAT ACT CCC CCA GGT-3', and the mixing molar ratio is 1: 2, obtaining a mixture Dox-Duplex, and adding the mPEG-SS-PEI-DSPE long chain and the mixture Dox-Duplex into deionized water; the mPEG-SS-PEI-DSPE has the structure of polyethylene glycol-disulfide bond-polyethyleneimine-distearoyl phosphatidyl ethanolamine, the molecular weight of PEG is 2000, the molecular weight of PEI is 1800, and the molar ratio is 1:1, uniformly stirring in an aqueous solution system, and performing ultrasonic treatment for 10-30 minutes to obtain an aqueous solution of mPEG-SS-PEI-DSPE-Dox-Duplex; wherein the mass ratio of the added mPEG-SS-PEI-DSPE to the added Dox-Duplex is 1-5: 1; the feeding ratio of the mPEG-SS-PEI-DSPE to the deionized water is 1 mg: 1-5 mL.
S2, dissolving glucose transporter inhibitor BAY-876 in chloroform, slowly dripping into the aqueous solution of mPEG-SS-PEI-DSPE-Dox-Duplex obtained in the step S1, heating while ultrasonic treatment is carried out until the liquid becomes clear and transparent, and then carrying out centrifugal freeze-drying to finally obtain BAY-876@ (mPEG-SS-PEI-DSPE-Dox-Duplex) nano self-assembly material; wherein the mass ratio of the added BAY-876 to the Dox-Duplex in the step S1 is 1: 1; the volume ratio of the trichloromethane to the deionized water in the step S1 is 1: 10-20.
Example (b):
a preparation method of BAY-876@ (mPEG-SS-PEI-DSPE-Dox-Duplex) nano self-assembly material (the specific process is shown in figure 1):
s1, mixing adriamycin and DNA ligand at room temperature to obtain mixture Dox-Duplex, weighing 50mg mPEG-SS-PEI-DSPE to disperse in 50mL deionized water, then adding 10mg Dox-Duplex to continue ultrasound for 20 minutes.
S2, dissolving 5mg of BAY-876 in 5mL of trichloromethane, slowly dropping the solution into the solution, stirring and ultrasonically treating the solution until the liquid becomes clear and transparent, and then centrifuging and freeze-drying the solution to obtain the BAY-876@ (mPEG-SS-PEI-DSPE-Dox-Duplex) nano self-assembly material.
The transmission electron microscope of the BAY-876@ (mPEG-SS-PEI-DSPE-Dox-Duplex) nano self-assembly material prepared in the above example is shown in FIG. 2, and the nano material with regular and uniform shape and the maximum particle size of about 20nm can be obviously observed.
The particle size distribution diagram of the BAY-876@ (mPEG-SS-PEI-DSPE-Dox-Duplex) nano self-assembly material prepared in the above example is shown in FIG. 3, and the nano material is obviously observed to be monodisperse, and the hydrated particle size is about 50-60 nm.
The BAY-876@ (mPEG-SS-PEI-DSPE-Dox-Duplex) nano self-assembly material prepared in the above example has the inhibition effect on glucose uptake and ATP synthesis of tumor cells (4T1 cells, mouse breast cancer cells) as shown in FIG. 4, and the glucose uptake content and ATP synthesis content of the tumor cells are continuously reduced within 72 hours, which indicates that the nanoparticles have excellent inhibition effect on the energy metabolism of tumors.
Claims (9)
1. A preparation method of a nano self-assembly material for inhibiting tumor cell glycometabolism is characterized by comprising the following steps:
s1, mixing adriamycin and DNA ligand at room temperature to obtain a mixture Dox-Duplex, adding the mPEG-SS-PEI-DSPE long chain and the mixture Dox-Duplex into deionized water, uniformly stirring in an aqueous solution system, and performing ultrasonic treatment for 10-30 minutes to obtain an aqueous solution of polyethylene glycol-disulfide bond-polyethyleneimine-distearoyl phosphatidyl ethanolamine mPEG-SS-PEI-DSPE-Dox-Duplex;
the base sequences of the DNA ligands are 5'-ACC TGG GGG AGT ATT GCG GAG GAA GGT-3' and 5'-ACC TTC CTC CGC AAT ACT CCC CCA GGT-3';
s2, dissolving a glucose transporter inhibitor BAY-876 in chloroform, slowly dropping the solution into the aqueous solution system of mPEG-SS-PEI-DSPE-Dox-Duplex obtained in the step S1, heating the solution under ultrasonic conditions, keeping the temperature not higher than 50 ℃ until the liquid becomes clear and transparent, centrifuging and freeze-drying the solution, and finally obtaining the nano self-assembled material with the structure of BAY-876@ (mPEG-SS-PEI-DSPE-Dox-Duplex).
2. The method for preparing nano self-assembly material for inhibiting tumor cell glycometabolism according to claim 1, wherein the molar ratio of the adriamycin and the DNA ligand mixed in step S1 is 1: 2.
3. the preparation method of the nano self-assembly material for inhibiting tumor cell glycometabolism according to claim 1, wherein the mass ratio of the added mPEG-SS-PEI-DSPE, Dox-Duplex and BAY-876 is 1-5: 1: 1.
4. The method for preparing a nano self-assembly material for inhibiting sugar metabolism of tumor cells according to claim 1, wherein the mPEG-SS-PEI-DSPE structure of step S1 is polyethylene glycol-disulfide bond-polyethyleneimine-distearoylphosphatidylethanolamine, wherein the molecular weight of polyethylene glycol is 2000 and the molecular weight of polyethyleneimine is 1800.
5. The method for preparing nano self-assembly material for inhibiting tumor cell glycometabolism according to claim 1, wherein the molar ratio of the mPEG-SS-PEI-DSPE long chain to the mixture Dox-Duplex added into deionized water in step S1 is 1: 1.
6. the method for preparing the nano self-assembly material for inhibiting sugar metabolism of tumor cells according to claim 1, wherein the volume ratio of the chloroform in step S2 to the deionized water in step S1 is 1: 10-20.
7. The method for preparing the nano self-assembly material for inhibiting sugar metabolism of tumor cells according to claim 1, wherein the feeding ratio of the mPEG-SS-PEI-DSPE and the deionized water in the step S1 is 1 mg: 1-5 mL.
8. The nano self-assembly material for inhibiting the sugar metabolism of tumor cells, prepared by the method according to any one of claims 1 to 7, is characterized in that the structure of the nano self-assembly material is BAY-876@ (mPEG-SS-PEI-DSPE-Dox-Duplex), wherein a mixture of adriamycin and DNA ligand is adsorbed with polyethyleneimine in a long chain of mPEG-SS-PEI-DSPE through electrostatic interaction, and BAY-876 is combined with distearoyl phosphatidyl ethanolamine and stored in the center of the nano self-assembly material.
9. The use of the nano self-assembled material for inhibiting sugar metabolism of tumor cells according to claim 8, in the preparation of a medicament for treating tumors, wherein the nano self-assembled material is used for inhibiting glucose metabolism and ATP production of tumors so as to limit growth and proliferation of tumor cells.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110442089.7A CN113274398B (en) | 2021-04-23 | 2021-04-23 | Nano self-assembly material for inhibiting tumor cell glycometabolism and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110442089.7A CN113274398B (en) | 2021-04-23 | 2021-04-23 | Nano self-assembly material for inhibiting tumor cell glycometabolism and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113274398A CN113274398A (en) | 2021-08-20 |
| CN113274398B true CN113274398B (en) | 2022-05-03 |
Family
ID=77277243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110442089.7A Active CN113274398B (en) | 2021-04-23 | 2021-04-23 | Nano self-assembly material for inhibiting tumor cell glycometabolism and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113274398B (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106798923B (en) * | 2015-11-26 | 2020-06-09 | 北京大学 | Function targeting carrier material distearoyl phosphatidyl ethanolamine-polyethylene glycol-polyethylene imine compound and liposome modified by same |
-
2021
- 2021-04-23 CN CN202110442089.7A patent/CN113274398B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN113274398A (en) | 2021-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ren et al. | Light-activated oxygen self-supplied starving therapy in near-infrared (NIR) window and adjuvant hyperthermia-induced tumor ablation with an augmented sensitivity | |
| CN108653754B (en) | Hyaluronic acid targeted polydopamine coated phase-change type liquid fluorocarbon nano ultrasonic contrast agent | |
| CN107007835B (en) | Prussian blue-loaded targeting nano-composite and preparation method thereof | |
| CN108653733A (en) | Polymer vesicle and the preparation of double load anthracene nucleus medicaments and photosensitizer with bubble formation function | |
| CN102675655A (en) | Water-soluble fullerene and preparation and application methods thereof | |
| CN114432265B (en) | Bionic nano delivery system loaded with bufalin and preparation method and application thereof | |
| Yang et al. | Advanced nanomedicines for the regulation of cancer metabolism | |
| Han et al. | The development of live microorganism-based oxygen shuttles for enhanced hypoxic tumor therapy | |
| Wu et al. | Size-transformable nanohybrids with pH/redox/enzymatic sensitivity for anticancer therapy | |
| Wang et al. | Progress and perspectives of platinum nanozyme in cancer therapy | |
| CN113274398B (en) | Nano self-assembly material for inhibiting tumor cell glycometabolism and preparation method and application thereof | |
| CN104587466A (en) | Protein-polypyrrole compound as well as preparation method and application of protein-polypyrrole compound derivative | |
| CN110251672B (en) | Nano diagnosis and treatment agent and preparation method and application thereof | |
| WO2022016555A1 (en) | Platinum-based drug-/photosensitizer-loaded protein nanoparticle, and preparation method therefor and application thereof | |
| Qiao et al. | Emerging platinum (0) nanotherapeutics for efficient cancer therapy | |
| CN106606783B (en) | A kind of targeting is passed altogether to be released the drug of photosensitizer and chemotherapeutics and passs release system | |
| Tang et al. | Cancer cell membrane biomimetic mesoporous nanozyme system with efficient ROS generation for antitumor chemoresistance | |
| CN114939165B (en) | Bimetal nanoparticle capable of reversing multi-drug resistance as well as preparation method and application thereof | |
| CN114848854B (en) | The method comprises the following steps of 131 I-HSA-ICG nano-particle and preparation method and application thereof | |
| CN109806404B (en) | Albumin nanoparticle capable of achieving two-stage oxygen delivery and preparation method and application thereof | |
| Cheng et al. | Folic acid mediated cisplatin magnetic nanodrug targeting in the treatment of oral squamous cell carcinoma | |
| Li et al. | Neutrophil membrane camouflaged hybrid nanozymes for enhanced starvation/photothermal tumor therapy | |
| Liu et al. | Functionalized Organic–Inorganic Liposome Nanocomposites for the Effective Photo-Thermal Therapy of Breast Cancer | |
| CN113845904B (en) | Preparation of boron-nitrogen doped graphene quantum dots and application of boron-nitrogen doped graphene quantum dots in boron neutron capture therapeutic drugs | |
| CN108671238A (en) | A kind of preparation method of the high tumor infiltrating albumin nano system of combination therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |